RxDoctor Payments Data

Terry Kersey, MD

Cardiovascular Disease · Rutherfordton, NCNPI 1093879074

Payments from drug & device makers

$137in general payments, 2019–2025

Across 10 payments — averaging $13.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$46
  • Johnson & Johnson$23
  • Novo Nordisk$16
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$13
  • Boston Scientific$13
  • AstraZeneca$13
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$137 in reported general payments places this provider in the 10th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$225,151
Medicare patients
1,150
Services billed
3,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban915$777,640
EntrestoSacubitril/Valsartan320$275,463
XareltoRivaroxaban206$200,908
JardianceEmpagliflozin143$96,056
Repatha SureclickEvolocumab44$43,071
MultaqDronedarone Hcl20$26,249
OzempicSemaglutide13$14,524
Praluent PenAlirocumab18$13,339
FarxigaDapagliflozin Propanediol23$12,767
Dabigatran EtexilateDabigatran Etexilate Mesylate35$10,549
Flecainide Acetate252$8,346
Ranolazine ErRanolazine113$6,864
Diltiazem 12hr ErDiltiazem Hcl13$5,252
Metoprolol Succinate447$5,139
Carvedilol746$4,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$46$275,463320 claims
Johnson & JohnsonXarelto$23$200,908206 claims
Boehringer IngelheimJardiance$12$96,056143 claims
Novo NordiskOzempic$16$14,52413 claims
AstraZenecaFarxiga$13$12,76723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Rutherfordton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →